Thymic malignancies: From clinical management to targeted therapies

Ronan Joseph Kelly, Iacopo Petrini, Arun Rajan, Yisong Wang, Giuseppe Giaccone

Research output: Contribution to journalArticle

Abstract

Purpose: A key challenge in the treatment of thymoma and thymic carcinoma (TC) is in improving our understanding of the molecular biology of these relatively rare tumors. In recent years, significant efforts have been made to dissect the molecular pathways involved in their carcinogenesis. Here we discuss the results of large-scale genomic analyses conducted to date and review the most active chemotherapies and targeted treatments. Methods: We reviewed the literature for chemotherapeutic trials in the last 20 years and trials involving targeted therapies between 1999 and 2010. The search was supplemented by a review of abstracts presented at the annual meetings of the American Society of Clinical Oncology (from 1999 to 2010), at the first International Conference on Thymic Malignancies in 2009, and at a follow-up meeting of the newly formed International Thymic Malignancies Interest Group in 2010. Results: Surgery remains the treatment of choice for operable tumors, whereas chemotherapy is standard in locally advanced and metastatic disease. Thus far, targeted therapies have been developed empirically. Histone deacetylase inhibitors have shown some activity in thymoma whereas sunitinib may be active in TC. There are no data to support the use of HER2- or EGFR-targeted therapies in thymic malignancies. Conclusion: Drug development for the treatment of thymic malignancies is difficult because of the rarity of these tumors. Ethnic differences are becoming apparent, with aggressive subtypes being observed in Asians and African Americans. Incremental improvements in our understanding of tumor biology suggest that molecular profiling- directed therapies may be the preferred route of investigation in the future.

Original languageEnglish (US)
Pages (from-to)4820-4827
Number of pages8
JournalJournal of Clinical Oncology
Volume29
Issue number36
DOIs
StatePublished - Dec 20 2011
Externally publishedYes

Fingerprint

Thymoma
Neoplasms
Therapeutics
Molecular Biology
Drug Therapy
Public Opinion
Histone Deacetylase Inhibitors
Asian Americans
African Americans
Carcinogenesis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kelly, R. J., Petrini, I., Rajan, A., Wang, Y., & Giaccone, G. (2011). Thymic malignancies: From clinical management to targeted therapies. Journal of Clinical Oncology, 29(36), 4820-4827. https://doi.org/10.1200/JCO.2011.36.0487

Thymic malignancies : From clinical management to targeted therapies. / Kelly, Ronan Joseph; Petrini, Iacopo; Rajan, Arun; Wang, Yisong; Giaccone, Giuseppe.

In: Journal of Clinical Oncology, Vol. 29, No. 36, 20.12.2011, p. 4820-4827.

Research output: Contribution to journalArticle

Kelly, RJ, Petrini, I, Rajan, A, Wang, Y & Giaccone, G 2011, 'Thymic malignancies: From clinical management to targeted therapies', Journal of Clinical Oncology, vol. 29, no. 36, pp. 4820-4827. https://doi.org/10.1200/JCO.2011.36.0487
Kelly, Ronan Joseph ; Petrini, Iacopo ; Rajan, Arun ; Wang, Yisong ; Giaccone, Giuseppe. / Thymic malignancies : From clinical management to targeted therapies. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 36. pp. 4820-4827.
@article{08d4ed97611043e5990c4b95f2396a17,
title = "Thymic malignancies: From clinical management to targeted therapies",
abstract = "Purpose: A key challenge in the treatment of thymoma and thymic carcinoma (TC) is in improving our understanding of the molecular biology of these relatively rare tumors. In recent years, significant efforts have been made to dissect the molecular pathways involved in their carcinogenesis. Here we discuss the results of large-scale genomic analyses conducted to date and review the most active chemotherapies and targeted treatments. Methods: We reviewed the literature for chemotherapeutic trials in the last 20 years and trials involving targeted therapies between 1999 and 2010. The search was supplemented by a review of abstracts presented at the annual meetings of the American Society of Clinical Oncology (from 1999 to 2010), at the first International Conference on Thymic Malignancies in 2009, and at a follow-up meeting of the newly formed International Thymic Malignancies Interest Group in 2010. Results: Surgery remains the treatment of choice for operable tumors, whereas chemotherapy is standard in locally advanced and metastatic disease. Thus far, targeted therapies have been developed empirically. Histone deacetylase inhibitors have shown some activity in thymoma whereas sunitinib may be active in TC. There are no data to support the use of HER2- or EGFR-targeted therapies in thymic malignancies. Conclusion: Drug development for the treatment of thymic malignancies is difficult because of the rarity of these tumors. Ethnic differences are becoming apparent, with aggressive subtypes being observed in Asians and African Americans. Incremental improvements in our understanding of tumor biology suggest that molecular profiling- directed therapies may be the preferred route of investigation in the future.",
author = "Kelly, {Ronan Joseph} and Iacopo Petrini and Arun Rajan and Yisong Wang and Giuseppe Giaccone",
year = "2011",
month = "12",
day = "20",
doi = "10.1200/JCO.2011.36.0487",
language = "English (US)",
volume = "29",
pages = "4820--4827",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "36",

}

TY - JOUR

T1 - Thymic malignancies

T2 - From clinical management to targeted therapies

AU - Kelly, Ronan Joseph

AU - Petrini, Iacopo

AU - Rajan, Arun

AU - Wang, Yisong

AU - Giaccone, Giuseppe

PY - 2011/12/20

Y1 - 2011/12/20

N2 - Purpose: A key challenge in the treatment of thymoma and thymic carcinoma (TC) is in improving our understanding of the molecular biology of these relatively rare tumors. In recent years, significant efforts have been made to dissect the molecular pathways involved in their carcinogenesis. Here we discuss the results of large-scale genomic analyses conducted to date and review the most active chemotherapies and targeted treatments. Methods: We reviewed the literature for chemotherapeutic trials in the last 20 years and trials involving targeted therapies between 1999 and 2010. The search was supplemented by a review of abstracts presented at the annual meetings of the American Society of Clinical Oncology (from 1999 to 2010), at the first International Conference on Thymic Malignancies in 2009, and at a follow-up meeting of the newly formed International Thymic Malignancies Interest Group in 2010. Results: Surgery remains the treatment of choice for operable tumors, whereas chemotherapy is standard in locally advanced and metastatic disease. Thus far, targeted therapies have been developed empirically. Histone deacetylase inhibitors have shown some activity in thymoma whereas sunitinib may be active in TC. There are no data to support the use of HER2- or EGFR-targeted therapies in thymic malignancies. Conclusion: Drug development for the treatment of thymic malignancies is difficult because of the rarity of these tumors. Ethnic differences are becoming apparent, with aggressive subtypes being observed in Asians and African Americans. Incremental improvements in our understanding of tumor biology suggest that molecular profiling- directed therapies may be the preferred route of investigation in the future.

AB - Purpose: A key challenge in the treatment of thymoma and thymic carcinoma (TC) is in improving our understanding of the molecular biology of these relatively rare tumors. In recent years, significant efforts have been made to dissect the molecular pathways involved in their carcinogenesis. Here we discuss the results of large-scale genomic analyses conducted to date and review the most active chemotherapies and targeted treatments. Methods: We reviewed the literature for chemotherapeutic trials in the last 20 years and trials involving targeted therapies between 1999 and 2010. The search was supplemented by a review of abstracts presented at the annual meetings of the American Society of Clinical Oncology (from 1999 to 2010), at the first International Conference on Thymic Malignancies in 2009, and at a follow-up meeting of the newly formed International Thymic Malignancies Interest Group in 2010. Results: Surgery remains the treatment of choice for operable tumors, whereas chemotherapy is standard in locally advanced and metastatic disease. Thus far, targeted therapies have been developed empirically. Histone deacetylase inhibitors have shown some activity in thymoma whereas sunitinib may be active in TC. There are no data to support the use of HER2- or EGFR-targeted therapies in thymic malignancies. Conclusion: Drug development for the treatment of thymic malignancies is difficult because of the rarity of these tumors. Ethnic differences are becoming apparent, with aggressive subtypes being observed in Asians and African Americans. Incremental improvements in our understanding of tumor biology suggest that molecular profiling- directed therapies may be the preferred route of investigation in the future.

UR - http://www.scopus.com/inward/record.url?scp=84555197165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555197165&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.36.0487

DO - 10.1200/JCO.2011.36.0487

M3 - Article

C2 - 22105817

AN - SCOPUS:84555197165

VL - 29

SP - 4820

EP - 4827

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 36

ER -